🚀AI’s current proof points in drug discovery – and the next frontier In an interview with The@BioCentury Show, Recursion CEO and President Najat Khan, PhD talked to executive editor@SelinaMKoch about the differentiators to look for as the TechBio industry matures. “The barolving around ‘what is the endgame?’” Najat says. “And the endgame is to make differentiated medicines that matter…no matter what dataset you have, what model you have, or what approaches you’re using.” She points out that while many early stage companies are focused on building models, Recursion is in the next stage of its evolution: delivering proof points. That requires an end-to-end approach, she says. “It's not enough to be better in just biology, chemistry, or the clinic. You have to use AI across the entire vertical tech stack.” Najat shares how she sees AI’s most measurable early advantages emerging in chemistry and clinical trial execution. In ClinTech, Najat notes that Recursion is applying AI to improve patient stratification, drive smarter trial design, and accelerate enrollment. The next frontier, she says, is “out-of-domain” prediction — the ability for models to make useful inferences in less-charted biological terrain. 👉 Listen to the full podcast herelnkd.in/eeDsbAZBpi

We’re excited to announce that industry veteran Vicki Goodman, M.D., will join Recursion as Chief Medical Officer effective April 6, 2026. Vicki is an accomplished physician-executive with 20+ years in oncology drug development, beginning as a Medical Officer at the U.S. FDA and roles at @Merck (contributing to programs such as KEYTRUDA), @bmsnews (OPDIVO, YERVOY), @GSK (leading dabrafenib through approval), and as CMO at Exelixis and @MuralOncology. She brings deep, practical regulatory strategy and development experience from start to finish with a clear regulatory vision to help Recursion translate scientific insight into disciplined, high-quality clinical programs as we advance our pipeline. We’re thrilled to have Vicki join the team and look forward to accelerating our progress to deliver medicines to patients. Read more: ir.recursion.com/news-releases/…